Results 141 to 150 of about 216,694 (240)

Histopathological Evidence of Neurodegenerative Pathology in Epilepsy: A Systematic Review

Annals of Clinical and Translational Neurology, Volume 13, Issue 8, Page 1530-1542, August 2026.
ABSTRACT Epilepsy affects > 50 million people worldwide and is associated with a disproportionate burden of cognitive impairment. Emerging evidence suggests that neurodegenerative proteinopathies, particularly hyperphosphorylated tau (p‐tau) and amyloid‐β (Aβ), may contribute to cognitive dysfunction in people with epilepsy (PWE), even in the absence ...
Syeda Amrah Hashmi, Aleksander Luniewski, Vanessa Smith, Matthew McCord, Jaideep Kapur, Mark Quigg, Catherine Joshua, Ifrah Zawar   +7 more
wiley   +1 more source

Correlation Is Not Prediction: Reassessing Predictive MRI Evidence in Guidelines for Persons With Relapsing-Remitting Multiple Sclerosis. [PDF]

J Cent Nerv Syst Dis
Minas D, Buchka S, Havla J, Mansmann U.
europepmc   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Early Upper Limb Motor Impairment in Multiple Sclerosis Across EDSS Levels: A Case–Control Study

Brain and Behavior, Volume 16, Issue 8, August 2026.
Upper limb function is impaired in people with multiple sclerosis compared with healthy controls, even at low levels of neurological disability. Patients are stratified by Expanded Disability Status Scale (EDSS) score (≤3.5 and >3.5) and assessed using objective upper limb measures.
Aitor Blázquez‐Fernández, Selena Marcos‐Antón, Cecilia Estrada‐Barranco, Patricia Martín‐Casas, Rosa María Ortiz‐Gutiérrez, Carmen Jiménez‐Antona, Sofía Laguarta‐Val, Roberto Cano‐de‐la‐Cuerda   +7 more
wiley   +1 more source

Identification of diagnostic biomarkers for relapsing-remitting multiple sclerosis in plasma by mass spectrometry-based proteomics. [PDF]

J Neuropathol Exp Neurol
García-Silva VM, Chicano-Galvez E, García-Sánchez MI, Peralbo-Molina Á, Hernández-Valladares M.   +4 more
europepmc   +1 more source

Retinal Layer Thickness for Risk Stratification of Progression Independent of Relapse Activity in Relapsing‐Remitting Multiple Sclerosis

Brain and Behavior, Volume 16, Issue 8, August 2026.
This study assessed the prognostic value of optical coherence tomography‐derived thicknesses of the peripapillary retinal nerve fiber and ganglion cell‐inner plexiform layer for identifying people with relapsing‐remitting multiple sclerosis at risk of progression independent of relapse activity (PIRA) from two German centers.
Andre Braginets, Frederike Cosima Oertel, Eva‐Maria Strauß, Carla Leutloff, Tanja Schmitz‐Hübsch, Friedemann Paul, Susanna Asseyer, Rebecca Wicklein, Bernhard Hemmer, Klemens Ruprecht, Hanna Gwendolyn Zimmermann, Benjamin Knier, Ting‐Yi Lin   +12 more
wiley   +1 more source

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort. [PDF]

J Neurol
Filippi M, D'Amico E, Brescia Morra V, Zanetta C, Zanghì A, Di Filippo PS, Longobardi E, Colombo E, Mirabella M, Conte A, Tomassini V, Masini C, Perosino V, Tortorella P, Rocca MA, MUPSO Study Group.   +15 more
europepmc   +1 more source

Oligodendrocyte and Astrocyte Dynamics During Short‐Term Cuprizone Treatment

Brain and Behavior, Volume 16, Issue 8, August 2026.
Early cuprizone exposure (3 days to 1 week) results in the loss of mature oligodendrocytes and a shift in astrocyte subtypes before overt demyelination occurs. A1 astrocytes remained non‐significant; however, A2 astrocytes increased, indicating a protective, pro‐repair astrocyte–oligodendrocyte interaction that may be crucial for therapeutic ...
Lana Frankle, Mercy Oso, Amanda Riley, Riely Tomor, Davi Cecconi Checan, Hannah Lee, Kole Jarzembak, Sarah Sternbach, John Shelestak, Jennifer McDonough, Robert Clements   +10 more
wiley   +1 more source

Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis. [PDF]

J Neurol
Hayes MTG, Beadnall HN, Merlo D, Monif M, Zhu C, Barnett M, Buzzard K, Horakova D, Kalincik T, Laureys G, Lui E, Lechner-Scott J, Nguyen AL, Patti F, Sima DM, Smeets D, Vaneckova M, Van Hecke W, Van Pesch V, van der Walt A, Butzkueven H.   +20 more
europepmc   +1 more source

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis

Journal of Neurochemistry, 2017
L. Novakova, M. Axelsson, M. Khademi, H. Zetterberg, K. Blennow, C. Malmeström, F. Piehl, T. Olsson, J. Lycke   +8 more
semanticscholar   +1 more source